arrow_back Back to App

Sickle Cell Disease Awareness Month: Supporting Research and Treatment Access

This resolution supports designating September as Sickle Cell Disease Awareness Month. Its aim is to educate communities about the disease, the need for research, early detection, and effective treatments. Citizens can expect increased awareness and potentially improved access to healthcare in the future.
Key points
Support for educational efforts on sickle cell disease, including early detection and treatment.
Call for the government to remove barriers to innovative therapies for sickle cell patients, especially within Medicaid and Medicare.
Encouragement to form an interagency cabinet to develop policies supporting equitable treatment access and addressing bias in the healthcare system.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HRES_692
Sponsor: Rep. Davis, Danny K. [D-IL-7]
Process start date: 2023-09-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing support for the designation of September 2023 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HRES_692.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-18.

What are the main provisions?

Key points include:

  • Support for educational efforts on sickle cell disease, including early detection and treatment.
  • Call for the government to remove barriers to innovative therapies for sickle cell patients, especially within Medicaid and Medicare.
  • Encouragement to form an interagency cabinet to develop policies supporting equitable treatment access and addressing bias in the healthcare system.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Davis, Danny K. [D-IL-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health